Drug Delivery Devices Market size is expected to be worth around USD 713.1 Billion by 2033, from USD 333.4 Billion in 2023

Snapshot img

Drug Delivery Devices Market Size 2024-2028

The drug delivery devices market size is forecast to increase by USD 85.1 billion at a CAGR of 6.2% between 2023 and 2028.

The market is experiencing significant growth due to the increasing prevalence of chronic conditions and the rising adoption of self-administering systems. Self-injectable devices, including auto-injectors and jet-injectors, are gaining popularity for their convenience and effectiveness in delivering drugs directly to the target site. However, bioavailability hurdles remain a challenge in oral delivery systems, leading to the increasing use of injectable routes. Pharmaceutical companies are investing heavily in research and development to address these challenges and create more efficient drug delivery systems.In healthcare, Retail pharmacies and hospital pharmacies are key distribution channels for these devices, ensuring easy access for patients. Stringent government regulations ensure the safety and efficacy of these devices, making them a reliable option for patients. The market is expected to continue growing as technology advances and new applications for drug delivery systems emerge.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

 The market represents a significant segment within the pharmaceutical industry, offering innovative solutions for the effective and efficient administration of active pharmaceutical ingredients (APIs) in various therapeutic areas. These devices cater to both chronic diseases and non-chronic diseases, and their usage extends to home-care environments, retail pharmacies, hospital pharmacies, and online pharmacies. Advanced technology plays a crucial role in the development of drug delivery devices. Next-generation technologies, such as self-administering systems, auto-injectors, pen injectors, jet-injectors, prefilled syringes, and smart sensors, have gained popularity due to their patient-friendly designs and improved accuracy. In the context of chronic diseases, drug delivery devices have proven to be essential for targeted medication delivery.
Biologics drugs, which often require specific delivery methods, have particularly benefited from these advancements. The pharmaceutical industry's focus on diagnosis and treatment has led to the integration of drug delivery devices in various vaccination drives and therapeutic areas. Oral drug delivery and injectable drug delivery systems have shown remarkable progress, offering enhanced patient compliance and convenience. Homecare solutions have emerged as a key area of growth within the market. These devices enable patients to administer medications in the comfort of their homes, reducing the need for frequent hospital visits and improving overall patient care.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Route Of Administration

  Oral
  Injectable
  Pulmonary
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia



  Rest of World (ROW)

By Route Of Administration Insights

The oral segment is estimated to witness significant growth during the forecast period.

The market for Drug Delivery Devices encompasses various types of devices used for administering drugs, including Injection Devices, Oral Drug Delivery, Topical Drug Delivery, Ophthalmic Drug Delivery, and Nasal Drug Delivery. Among these, the segment for Oral Drug Delivery is significant due to its ease of use, non-invasive nature, and cost-effectiveness. This segment includes drugs in the form of capsules, tablets, syrups, solutions, and suspensions

Furthermore, orally administered drugs can be targeted to specific areas within the gastrointestinal tract to treat various conditions, including cancer, inflammation, infections, and bowel diseases. Advancements in pharmaceutical technologies and oral drug delivery systems, such as lipid-based carriers, nanocarriers, and micelles, are enhancing oral drug absorption, thereby improving therapeutic effectiveness. Hence, such factors are fuelling the growth of this segment during the forecast period.

Get a glance at the market report of share of various segments Request Free Sample

The oral segment was valued at USD 85.50 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 52% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions Request Free Sampl

Global Drug Delivery Devices Market was valued at USD 240.62 Billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 7.80% through 2029.

The global Connected Drug Delivery Devices Market size was estimated at US$ 330 Million in 2021, and is expected to reach US$ 1.6 Billion by 2028, expanding at a stellar CAGR of 23.6%.

How The Market Progressed Till June 2022?

Connected Drug Delivery Devices Industry Report Scope

Non-Invasive drug delivery devices market is segmented into products types, application. Market to grow at a CAGR of 23.13% during forecast period 2019 to 2025. Non-Invasive drug delivery devices market report by BIS Research provides deep market insight that will help your business to grow.

Connected Drug Delivery Devices Market Report is Segmented by Product Type(Connected Sensors [Connected Inhaler Sensors and More] and Integrated Connected Devices [Connected Inhalers and More), Technology (Bluetooth, Near-Field Communication and More), End User (Healthcare Providers, Homecare and More), Application (Respiratory Diseases, Diabetes and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD).

The global Subcutaneous Drug Delivery Devices Market in terms of revenue was estimated to be worth $30.43 bn in 2023 & is poised to reach $53.50 bn by 2032, growing at a CAGR of 6.5% from 2024 to 2032.

The targeted drug delivery device market was valued at $427 million in 2026 to $2,153 million by 2035, representing a CAGR of 19.7%.

The global drug delivery devices market size was worth more than USD 301.94 billion in 2024 and is poised to witness a CAGR of over 5.8%, crossing USD 628.4 billion revenue by 2037. Injectable segment is expected to achieve 39% share by 2037, due to advances in injectable drug delivery techniques and rising global vaccination efforts.

• The global industry was valued at US$ 390.7 Mn in 2023
• It is expected to grow at a CAGR of 6.8% from 2024 to 2034 and reach US$ 796.1 Mn by the end of 2034

On-body Drug Delivery Devices Market Overview

Regional Analysis of On-body Drug Delivery Devices Market

On-body Drug Delivery Devices Market Snapshot

United Kingdom Drug Delivery Devices Market Report is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, Infusion Pumps, and More), Route of Administration (Injectable, Inhalational, Transdermal, and More), Application (Diabetes, Respiratory Diseases, Oncology, and More), and End User (Hospitals, Ambulatory Surgical Centers, and More). The Market and Forecasts are Provided in Terms of Value (USD).

Global connected drug delivery devices market size is expected to grow from USD 4.4 bn in 2024 to USD 4.8 bn in 2025 and USD 12.7 bn by 2035, at CAGR of 10.1%

France Drug Delivery Devices Market Report is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, Infusion Pumps and More), Route of Administration (Injectable, Inhalational, Transdermal and More), Application (Diabetes, Oncology, Cardiovascular Diseases and More), End User (Hospitals, Ambulatory Surgical & Specialty Clinics and More). The Market and Forecasts are Provided in Terms of Value (USD).

Global transmucosal drug delivery devices market was valued at USD 46.63 Bn in 2024 and is predicted to USD 86.64 Bn by 2034, with a CAGR of 6.39%.

Drug Delivery Devices Market size was valued at USD 2.13 Billion in 2022 and is projected to reach USD 7.96 Billion by 2030 growing at a CAGR of 16.27% From 2024-2030.The global Drug Delivery Devices Market is expanding primarily due to the increasing prevalence of the chronic disease across the globe. Due to lifestyle choices and lack of physical exercise, the cases of diabetes, cardiovascular diseases, and cancer have exponentially increased in the past decade. This has promoted the key players to launch innovative medications and invest heavily in R&D activities. Such developments have greatly propelled the market for drug-delivery devices. The leading market players are introducing innovative products that offer better drug efficacy while reducing side effects, which is expected to open many attractive opportunities during the forecast period.

Drug Delivery Devices Market Report is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, and More), Route of Administration (Injectable, Inhalational and More), Technology (Conventional Mechanical, Needle-Free Jet and More), Application (Diabetes Mellitus, Oncology, and More), End User (Hospitals, Ambulatory Surgical Centers, and More). The Market and Forecasts are Provided in Terms of Value (USD).

The global implantable drug delivery devices market size reached USD 15.24 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 27.58 Billion by 2033, exhibiting a growth rate (CAGR) of 6.47% during 2025-2033. The increasing prevalence of chronic diseases, rising demand for minimally invasive procedures, the growing geriatric population susceptible to chronic disorders, and rapid technological advancements in implantable devices are some of the key factors driving the market.

IMARC Group provides an analysis of the key trends in each segment of the global implantable drug delivery devices market, along with forecasts at the global, regional, and country levels from 2025-2033. Our report has categorized the market based on product type, technology, application, and end user.

Drug Delivery Devices Market Outlook

According to our latest research, the global drug delivery devices market size in 2024 stands at USD 52.7 billion, reflecting robust industry momentum driven by the growing demand for innovative and patient-centric drug administration solutions. The market is projected to expand at a CAGR of 6.3% from 2025 to 2033, reaching an estimated value of USD 91.5 billion by the end of the forecast period. This growth trajectory is primarily underpinned by advancements in biologics, the increasing prevalence of chronic diseases, and the rising adoption of self-administration devices that enhance patient compliance and therapeutic outcomes.

One of the foremost growth factors propelling the drug delivery devices market is the escalating incidence of chronic diseases such as diabetes, cancer, and cardiovascular disorders worldwide. The global burden of these diseases necessitates efficient, safe, and targeted drug delivery systems to improve patient outcomes and reduce healthcare costs. With the emergence of biologics and personalized medicine, there is a heightened demand for sophisticated delivery platforms that can ensure precise dosing, minimize side effects, and offer convenience for long-term therapy management. Furthermore, the aging population, particularly in developed regions, is contributing significantly to the uptake of advanced drug delivery devices, as older adults often require regular medication and benefit from devices that facilitate ease of use and adherence.

Technological innovation represents another critical driver for the drug delivery devices market. Companies are investing heavily in research and development to introduce next-generation devices that integrate digital health features, such as connectivity for remote monitoring and data analytics. The integration of smart technologies not only enhances medication management but also empowers healthcare providers and patients with real-time insights into treatment efficacy and adherence patterns. Additionally, the development of needle-free injectors, microneedle patches, and wearable infusion pumps is transforming the landscape by offering less invasive and more comfortable alternatives to traditional methods. Regulatory agencies are also streamlining approval pathways for novel devices, encouraging manufacturers to accelerate product launches and meet evolving patient needs.

Another pivotal growth catalyst is the shift towards home-based healthcare and self-administration of medication, a trend that was notably accelerated by the COVID-19 pandemic. Patients and healthcare systems alike are prioritizing drug delivery devices that enable safe and effective administration outside of clinical settings, reducing the burden on hospitals and clinics. The proliferation of home care and ambulatory services has driven demand for user-friendly, portable, and reliable drug delivery solutions. In parallel, increased awareness and education regarding chronic disease management are fostering greater adoption of these devices across diverse demographics. This paradigm shift is supported by collaborations between device manufacturers, pharmaceutical companies, and digital health providers, creating integrated solutions that address both clinical and lifestyle needs.

From a regional perspective, North America continues to dominate the drug delivery devices market, accounting for the largest share in 2024 due to its advanced healthcare infrastructure, high prevalence of chronic diseases, and strong presence of leading industry players. Europe follows closely, benefiting from supportive government policies, growing investment in healthcare innovation, and a rising geriatric population. The Asia Pacific region, however, is anticipated to witness the fastest growth rate over the forecast period, driven by expanding healthcare access, increasing healthcare expenditure, and a burgeoning patient pool in countries such as China and India. Latin America and the Middle East & Africa are also poised for steady growth, supported by improving healthcare systems and rising awareness of advanced drug delivery technologies.

The global drug delivery systems market size exceeded USD 47.47 billion in 2024 and is set to expand at a CAGR of over 8.3%, surpassing USD 133.84 billion revenue by 2037. Diabetes segment is poised to capture 33% share by 2037, attributed to rising number of diabetes patients globally and the growing use of insulin injections among diabetes patients.

Intranasal Drug Delivery Devices Market is growing with a CAGR of 10.0% in the prediction period and it crosses USD 3.65 Bn by 2032 from USD 1.87 Bn in 2025.